Comparison · NCT04462536-e95d11aa
Nerinetide vs Placebo: Number of Participants Exhibiting a Worsening of Their Index Stroke.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nerinetide vs Placebo: Number of Participants Exhibiting a Worsening of Their Index Stroke. Trial comparisons, record NCT04462536-e95d11aa. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04462536-e95d11aa
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.167 | 0.136 | 0.205 | wilson | |
| Risk in group 2 | 0.172 | 0.138 | 0.212 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00432 | -0.0554 | 0.046 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.975 | 0.724 | 1.31 | log | |
| Odds ratio, group 1 over group 2 | 0.97 | 0.677 | 1.39 | log | |
| Number needed to treat, for one fewer participant with the outcome on Nerinetide than on Placebo | 232 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nerinetide | Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes~Nerinetide: Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes | 76 | 454 | OG001 |
| Group 2 | Placebo | Vehicle only~Placebo: Vehicle only | 68 | 396 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Exhibiting a Worsening of Their Index Stroke.
- Description
Worsening of stroke is defined as (A) progression, or hemorrhagic transformation of the index stroke, as documented by medical imaging that is (a) life-threatening requiring intervention and/or (b) results in increased disability as gauged by a ≥4 point increase from lowest NIHSS during hospitalization or (B) results in death from the index stroke.
- Time frame
- 90 days
- Population
- ITT Population
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis
- NCT number
- NCT04462536
- Phases
- PHASE3
- Conditions
- Stroke, Acute
- Interventions
- Placebo, Nerinetide
- Lead sponsor
- NoNO Inc.
- Results first posted
- 2025-06-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04462536?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04462536-e95d11aa